Seoul, Seoul, South Korea
I am a life science leader with over 25 years of experience in developing and commercializing innovative solutions for drug discovery, genomics, proteomics, and specialty markets. As ex-vice President and General Manager of APAC at Caliper, PerkinElmer and Thermofisher, I was responsible for establishing and growing our regional presence and business in the fast-growing and dynamic Asia-Pacific market, leveraging my strong network, market knowledge, and strategic thinking. I have a proven track record of achieving significant business impact globally, working with start-ups and global organizations, and managing diverse teams and portfolios. I have a Ph.D in Chemistry and a background in R&D, operations, marketing, and business development, with a focus on NGS, imaging, and precision medicine. I am passionate about creating brand awareness, defining and executing strategic campaigns, and developing international distribution channels. I am motivated by the mission of providing disruptive technology platforms and solutions that revolutionize the future of biohealthcare and personalized medicine.
I am delighted to welcome Dr. Young K. Yun to RocGene as our Overseas Vice President and Chief Business Officer. In this role, Dr. Yun will lead the company's international business expansion comprehensively, participate in the formulation of our global strategic planning, devise and steer the growth strategies for our international operations, foster cross-departmental collaboration, drive the expansion into international markets, and bridge access to the global market. Dr. Yun graduated from Ohio University in 1995 with a Ph.D. in Organic Chemistry. As for 26-year career in the life sciences field, Dr. Yun has held core management positions at various top medical enterprises, including Fortis Life Sciences, SoulBrain, Avatamed, ThermoFisher Sci, and PerkinElmer. With 26 years of experience in product development and commercialization, Dr. Yun possesses global management and operational expertise, successfully managing cross-border collaborations and distribution networks, particularly with a strong foundation and a track record of growth in the Asia-Pacific region. Prior to joining RocGene, Dr. Yun had an in-depth and comprehensive understanding of our company's products and technological applications. I am confident that his extensive expertise in the life sciences field, coupled with his vast international market experience, will propel RocGene towards an international breakthrough. I warmly welcome Dr. Yun to our team and look forward to working together towards an even brighter future for RocGene. May his endeavors within the company be fruitful and successful!...President, George Guo MBA
I am honored to announce that Young Yun is joining Fortis as Vice President and General Manager of APAC and establishing our regional HQ in Seoul, Korea. Young brings a wealth of regional and industry—both MNC and start up—experience making him uniquely qualified for this important commercial role. We look forward to his leadership and contribution!...Brian Kim, CEO & President Fortis Life Sciences, Waltham, MA, U.S.A
Today seems to become a major milestone in my professional career as I determined to join SoulBrain Holdings, BioHealthacre division, a company which provides a series of disruptive technology platforms and solutions revolutionizing the future of biohealthcare and personalized medicines. I want to take this opportunity to welcome you to SoulBrain Holdings, introduce myself as Executive Director/Chief Business Officer under Bio/Healthcare division, and encourage you to learn more about our works and missions to address the medical unmet needs. I traveled the world on behalf of world leading edge pharmaceutical and life science companies over the last 25 years and I can witness that there are so much never-ending medical unmet needs which we as the team may be able to address and provide the resolutions from multi-omics perspectives. SoulBrain Holdings started making strategic and financial investments into Bio/Healthacre since 2015 and the slide shot would tell you where were are now and where we are heading toward. We are in the middle of opening up the state of art core facility of “Translational Proteomic Centre” in PanKyo, 30 mins away from downtown Seoul and inside our headquarter of SoulBrain Central Research centre. We will be forming a group of brilliant minds who can work on both Brain related diseases and ImmunoTherapy.
AVATAMED is a spin-off company from A*STAR established in 2019 with the aim of giving most optimum treatment solutions to individual cancer patients. Taking over the technological potential of AVATASCAN & Avatamed, which has been developed by Samsung Medical Center for extended period of time, we aim to provide innovative disruptive technologies to the global precision oncology market. We will provide a better life for individual cancer patients through an distinctive drug development platform and a strong global network.